05:51 AM EDT, 05/07/2024 (MT Newswires) -- GSK (GSK) and BioVersys have expanded their collaboration to speed up development of alpibectir, a potential tuberculosis treatment, BioVersys said Tuesday.

As part of the deal, GSK will take a 12.3 million Swiss franc ($13.5 million) stake in BioVersys in the latter's latest investment round. GSK and BioVersys will collaborate beyond an ongoing phase 2a study of alpibectir among patients in South Africa.

BioVersys is a clinical-stage biopharmaceutical company focusing on antibacterial treatments for drug-resistant bacteria.

Price: 43.38, Change: -0.07, Percent Change: -0.16